Page 465 - TBE_Book_V2_2019

Chapter 14: Prevention

33. WHO. Vaccines against tick-borne 41. Kollaritsch H, Krasilnikov V, Holzmann H,
encephalitis (TBE): WHO position paper, et al. Background Paper on Vaccines and
10 June, 2011. Wkly Epidemiol Rec. Vaccination Against Tick-borne
2011;86:241-56. Encephalitis (TBE). Geneva, WHO
Strategic Advisory Group of Experts on
34. Leonova GN, Pavlenko EV. Immunization 2011.
Characterization of neutralizing antibodies
to Far Eastern tick-borne encephalitis 42. Holzmann H, Vorobyova MS, Ladyzhenskaya IP,
virus subtype and the antibody avidity for et al. Molecular epidemiology of tick-borne
four tick-borne encephalitis vaccines in encephalitis virus: cross-protection between
humans. Vaccine. 2009;27:2899-904. European and Far Eastern subtypes. Vaccine.
1992;10:345-9.
35. Heinz FX, Holzmann H, Essl A, Kundi M. 43. Orlinger KK, Hofmeister Y, Fritz R, et al. A
Field effectiveness of vaccination against tick-borne encephalitis virus vaccine based
tick-borne encephalitis. Vaccine. on the European prototype strain induces
2007;25:7559-67.
broadly reactive cross-neutralizing
antibodies in humans. J Infect Dis.
36. Heinz FX, Stiasny K, Holzmann H, et al. 2011;203:1556-64.
Vaccination and tick-borne encephalitis,
central Europe. Emerg Infect Dis. 44. Domnich A, Panatto D, Arbuzova EK, et al.
2013;19:69-76.
Immunogenicity against Far Eastern and
Siberian subtypes of tick-borne
37. Schosser R, Reichert A, Mansmann U, encephalitis (TBE) virus elicited by the
Unger B, Heininger U, Kaiser R. Irregular currently available vaccines based on the
tick-borne encephalitis vaccination European subtype: systematic review and
schedules: the effect of a single catch-up meta-analysis. Hum Vaccin Immunother.
vaccination with FSME-IMMUN. A 2014;10:2819- 33.
prospective non-interventional study.
Vaccine. 2014;32:2375-81.
45. Beck Y, Fritz R, Orlinger K, et al.
Molecular Basis of the Divergent
38. Rendi-Wagner P, Kundi M, Zent O, et al. Immunogenicity of Two Pediatric Tick-
Immunogenicity and safety of a booster Borne Encephalitis Virus Vaccines. J
vaccination against tick-borne encephalitis Virol. 2015;90:1964-72.
more than 3 years following the last
immunisation. Vaccine. 2004;23:427-34.
46. Rendi-Wagner P, Zent O, Jilg W, Plentz A, Beran
J, Kollaritsch H. Persistence of antibodies after
39. Jarmer J, Zlatkovic J, Tsouchnikas G, et al. vaccination against tick-borne encephalitis. Int
Variation of the specificity of the human J Med Microbiol. 2006;296 Suppl 40:202-7.
antibody responses after tick-borne
encephalitis virus infection and 47. Paulke-Korinek M, Kundi M, Laaber B, et al.
vaccination. J Virol. 2014;88:13845-57.
Factors associated with seroimmunity against
tick-borne encephalitis virus 10 years after
40. Holzmann H, Kundi M, Stiasny K, et al. booster vaccination. Vaccine. 2013;31:1293-7.
Correlation between ELISA,
hemagglutination inhibition, and 48. Paulke-Korinek M, Rendi-Wagner P, Kundi M,
neutralization tests after vaccination Laaber B, Wiedermann U, Kollaritsch H.
against tick-borne encephalitis. J Med Virol. Booster vaccinations against tick-borne
1996;48:102-7. encephalitis: 6 years follow-up indicates long-
term protection. Vaccine. 2009;27:7027-30.

467
460